UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • May

    27

    My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

    May

    24

    UCB’s Community Health Fund Applications are Open for Organizations Supporting the Mental Health of Young People and those Displaced Due to Conflict

    May

    23

    UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

    May

    23

    First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

    May

    20

    Recognizing the Importance of Clinical Studies

    Clinical studies are an essential part of biopharmaceutical research on the journey to discover, develop and deliver new solutions to people living with severe diseases. This Clinical Trial Awareness week, UCB thanks all of the participants in UCB studies and the dedicated researchers doing this important work.

    May

    17

    Prioritizing Mental Health for our People, Patients, and Purpose

    Mental health is top of mind at UCB as we work to prioritize the well-being of our people and the patients we serve. A core pillar of our sustainable business approach, we understand that delivering innovative solutions for patients begins with supporting the physical, mental, and social well-being of our employees, their families, and communities, now and in the future. This Mental Health Awareness Month, learn how we’re supporting mental wellness for our people, patients, and our purpose. 

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    May

    10

    Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

    UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    May

    02

    JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)